SCHEMBL995243

SCHEMBL995243

COC(=O)CCC(C)(O)CCCC(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
CDC25B P30305 1/20 0.39
CA12 O43570 2/20 0.37
CA14 Q9ULX7 2/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
RECQL P46063 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 1/20 0.35
LMNA P02545 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SLC1A1 P43005 1/20 0.33
KDM4C Q9H3R0 2/20 0.33
KDM4A O75164 1/20 0.33
PHF8 Q9UPP1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28029276 0.84 MEN1 (0.39) TSHRPTPN2PTPN1CDC25BCA12
SCHEMBL11925945 0.81 GPR84 (0.41) TSHRL3MBTL1RECQLMEN1KMT2A
SCHEMBL130826 0.78 TSHR (0.64) TSHRPTPN1CA12CA14CA7
SCHEMBL995832 0.77 TSHR (0.61) TSHRCA12CA14CA7CA9
SCHEMBL11925944 0.76 TSHR (0.39) TSHRCA12CA14L3MBTL1RECQL
SCHEMBL8212898 0.76 MEN1 (0.47) PTPN2PTPN1CDC25BL3MBTL1MEN1
SCHEMBL11668697 0.76 ALOX15 (0.47) PTPN2PTPN1CDC25BL3MBTL1MEN1
SCHEMBL17369070 0.76 TSHR (0.37) TSHRCA12CA14CA7CA9
SCHEMBL2254699 0.75 TSHR (0.58) TSHRCA12CA14CA7CA9
SCHEMBL19281387 0.75 TSHR (0.58) TSHRCA12CA14CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015397-A1 Selective Aliphatic C-H Oxidation THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2011-01-20 US disclosed
US-7829342-B2 composition including a complex of a metal, a tetradentate ligand, at least one ancillary ligand, and a counterion is used for selective sp3 C H bond oxidation; includes a N-heterocyclic-N,N'-bis(pyridyl)-ethane-1,2-diamine group or a N,N'-bis(heterocyclic)-N,N'-bis(pyridyl)-ethane-1,2-diamine group THE BOARD OF TRUSTEES OF THE UNIVERSIY OF ILLINOIS (US) 2010-11-09 US disclosed
US-20090221083-A1 Selective Aliphatic C-H Oxidation BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015397-A1 Selective Aliphatic C-H Oxidation AOC3, SOD3, AP3S1 TSHR 3550/4885PTPN2 1593/4885PTPN1 1257/4885
US-20090221083-A1 Selective Aliphatic C-H Oxidation AOC3, SOD3, AP3S1 TSHR 3550/4885PTPN2 1593/4885PTPN1 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.